Literature DB >> 23361904

Standardization of bleeding assessment in immune thrombocytopenia: report from the International Working Group.

Francesco Rodeghiero1, Marc Michel, Terry Gernsheimer, Marco Ruggeri, Victor Blanchette, James B Bussel, Douglas B Cines, Nichola Cooper, Bertrand Godeau, Andreas Greinacher, Paul Imbach, Mehdi Khellaf, Robert J Klaassen, Thomas Kühne, Howard Liebman, Maria Gabriella Mazzucconi, Adrian Newland, Ingrid Pabinger, Alberto Tosetto, Roberto Stasi.   

Abstract

In a previous publication on new terminology, definitions, and outcome criteria for immune thrombocytopenia (ITP), the International Working Group (IWG) on ITP acknowledged that response to treatment should consist of clinically meaningful end points such as bleeding manifestations and that platelet count may not be the ideal parameter for capturing the benefits of therapy. The IWG now proposes a consensus-based ITP-specific bleeding assessment tool (ITP-BAT) with definitions and terminology consistent with those adopted for other bleeding disorders. Bleeding manifestations were grouped into three major domains: skin (S), visible mucosae (M), and organs (O), with gradation of severity (SMOG). Each bleeding manifestation is assessed at the time of examination. Severity is graded from 0 to 3 or 4, with grade 5 for any fatal bleeding. Bleeding reported by the patient without medical documentation is graded 1. Within each domain, the same grade is assigned to bleeding manifestations of similar clinical impact. The "worst bleeding manifestation since the last visit" (observation period) is graded (a suitable database collection form is provided), and the highest grade within each domain is recorded. The SMOG system provides a consistent description of the bleeding phenotype in ITP, and the IWG unanimously supports its adoption and validation in future clinical studies.

Entities:  

Mesh:

Year:  2013        PMID: 23361904     DOI: 10.1182/blood-2012-07-442392

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  45 in total

1.  Risk factors for skin, mucosal, and organ bleeding in adults with primary ITP: a nationwide study in Japan.

Authors:  Takaaki Hato; Naoki Shimada; Yoshiyuki Kurata; Masataka Kuwana; Kingo Fujimura; Hirokazu Kashiwagi; Toshiro Takafuta; Mitsuru Murata; Yoshiaki Tomiyama
Journal:  Blood Adv       Date:  2020-04-28

2.  Application of ITP-BAT bleeding score in clinical practice.

Authors:  Meet Kumar; Shyamali Dutta; Maitryee Bhattyacharyya
Journal:  Int J Hematol       Date:  2014-11-21       Impact factor: 2.490

3.  Updated international consensus report on the investigation and management of primary immune thrombocytopenia.

Authors:  Drew Provan; Donald M Arnold; James B Bussel; Beng H Chong; Nichola Cooper; Terry Gernsheimer; Waleed Ghanima; Bertrand Godeau; Tomás José González-López; John Grainger; Ming Hou; Caroline Kruse; Vickie McDonald; Marc Michel; Adrian C Newland; Sue Pavord; Francesco Rodeghiero; Marie Scully; Yoshiaki Tomiyama; Raymond S Wong; Francesco Zaja; David J Kuter
Journal:  Blood Adv       Date:  2019-11-26

4.  Bleeding tendency and platelet function during treatment with romiplostim in children with severe immune thrombocytopenic purpura.

Authors:  Elena V Suntsova; Irina M Demina; Anastasia A Ignatova; Nikolay M Ershov; Natalia M Trubina; Juliya Dobrynina; Irina V Serkova; Zhanna S Supik; Ekaterina V Orekhova; Lili A Hachatryan; Natalia N Kotskaya; Aleksey V Pshonkin; Aleksey A Maschan; Galina A Novichkova; Mikhail A Panteleev
Journal:  Int J Hematol       Date:  2017-03-07       Impact factor: 2.490

5.  Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia.

Authors:  Tadeusz Robak; Maciej Kaźmierczak; Isidro Jarque; Vasile Musteata; Jacek Treliński; Nichola Cooper; Peter Kiessling; Ute Massow; Franz Woltering; Rose Snipes; Juan Ke; Grant Langdon; James B Bussel; Stephen Jolles
Journal:  Blood Adv       Date:  2020-09-08

Review 6.  Management of newly diagnosed immune thrombocytopenia: can we change outcomes?

Authors:  Cindy E Neunert
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

Review 7.  Management of newly diagnosed immune thrombocytopenia: can we change outcomes?

Authors:  Cindy E Neunert
Journal:  Blood Adv       Date:  2017-11-14

Review 8.  Initial management of immune thrombocytopaenia in adults based on risk stratification.

Authors:  Jaydev Manikkam Umakanthan; Prajwal Dhakal; Krishna Gundabolu; Avyakta Kallam; Daniel R Almquist; Vijaya Raj Bhatt
Journal:  Postgrad Med J       Date:  2019-07-18       Impact factor: 2.401

9.  Laparoscopic splenectomy for immune thrombocytopenia (ITP): long-term outcomes of a modern cohort.

Authors:  Luciano Tastaldi; David M Krpata; Ajita S Prabhu; Clayton C Petro; Ivy N Haskins; Arielle J Perez; Hemasat Alkhatib; Iago Colturato; Chao Tu; Alan Lichtin; Michael J Rosen; Steven Rosenblatt
Journal:  Surg Endosc       Date:  2018-07-09       Impact factor: 4.584

Review 10.  Severe bleeding events in adults and children with primary immune thrombocytopenia: a systematic review.

Authors:  C Neunert; N Noroozi; G Norman; G R Buchanan; J Goy; I Nazi; J G Kelton; D M Arnold
Journal:  J Thromb Haemost       Date:  2015-01-14       Impact factor: 5.824

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.